Meta-Analysis of Cognition in Parkinson's Disease Mild Cognitive Impairment and Dementia Progression

Elizabeth R Wallace1, Suzanne C Segerstrom2, Craig G van Horne3,4

  • 1Department of Psychology, University of Kentucky, Lexington, KY, USA. liz.wallace@uky.edu.

Neuropsychology Review
|April 16, 2021
PubMed

Insights

This meta-analysis defines the cognitive profile of mild cognitive impairment in Parkinson's Disease (PD-MCI). Executive dysfunction is a key predictor of progression to Parkinson's disease dementia (PDD).

Area of Science:

  • Neuroscience
  • Cognitive Neurology
  • Geriatric Psychiatry

Background:

  • Parkinson's Disease (PD) is associated with mild cognitive changes, including executive dysfunction.
  • Approximately 30% of individuals with PD progress to Parkinson's disease dementia (PDD).
  • Mild Cognitive Impairment (MCI) serves as a transitional state, and Parkinson's Disease Mild Cognitive Impairment (PD-MCI) is a recognized risk factor for PDD.

Purpose of the Study:

  • To define the typical cognitive profile of PD-MCI by aggregating data from cross-sectional studies.
  • To identify cognitive predictors of progression from PD-MCI to PDD using longitudinal studies.
  • To provide comprehensive meta-analytic effect sizes for cognitive domains in PD-MCI.

Main Methods:

  • A meta-analysis of 92 cross-sectional studies comparing PD-MCI and cognitively normal PD (PD-CN) groups.
  • A meta-analysis of 5 longitudinal studies tracking PD-MCI conversion to PDD.
  • Random effects models were used to calculate aggregated effect sizes (Hedges' g) for cognitive domains.

Main Results:

  • Cross-sectional analyses revealed a large overall effect size (g = 0.83), with cognitive screeners showing the largest effect (g = 1.09).
  • Longitudinal analyses indicated a moderate overall effect size (g = 0.47), with executive functioning measures demonstrating the largest effect (g = 0.70).
  • Longitudinal findings were robust, characterized by low heterogeneity.

Conclusions:

  • This meta-analysis provides the first comprehensive overview of cognitive outcomes in PD-MCI and predictors of PDD conversion.
  • Executive dysfunction is a significant cognitive domain associated with PD-MCI and its progression to PDD.
  • Future research should focus on visuospatial skills, visual memory, and longitudinal executive dysfunction in PD-MCI.

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
677
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.0K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.1K
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
275
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
290
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
459